Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
Active, not recruiting · NCT07480863 · Registry updated 2026-04-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL | B-cell neoplasm, Hemic and Lymphatic Diseases, Lymphoma, B-Cell, Marginal Zone, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-04-02 | NCT07480863 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| BioRay Pharmaceutical Co., Ltd. | 9 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 294 |
| InnoCare Pharma Inc. | 3 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, beijing, | Beijing | China | 3 |